The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in research because ...

The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

Alzheimer’s disease is the leading cause of dementia in the UK. It’s a complex, challenging, and devastating condition that causes a gradual decline in a person’s cognition, including memory and ...

A study suggests that menopausal hormone therapy (MHT) might have moderate effects on brain health, but this depends on past ...

Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...

A clinical trial is testing whether an existing drug could benefit patients with Alzheimer’s disease, in hopes of making ...

Leqembi, first FDA-approved Alzheimer's drug, faces EMA rejection, but shares could potentially surge soon. See why I rate ...

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a ...

Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s ...

Health Alzheimer's Disease study plans to study 2,000 volunteers' brain scans and blood work to identify biomarkers of dementia-causing diseases sooner.